托法替布与乌司奴单抗治疗溃疡性结肠炎的真实世界疗效比较:TORUS研究
TORUS研究为多中心真实世界证据研究,连续纳入既往暴露于至少一种抗TNF药物的溃疡性结肠炎患者,比较托法替布与乌司奴单抗的有效性。第16周时两组无激素症状缓解率相似(37.8% vs 35.8%),但在既往暴露≥3种生物制剂的患者中托法替布更有效。两组在临床缓解、组织学与内镜改善及停药风险方面无显著差异。
要点
- 抗TNF失败后UC患者中,托法替布与乌司奴单抗诱导和维持无激素缓解疗效相似
- 既往暴露≥3种生物制剂者,托法替布第16周无激素症状缓解率更高
- 任何生物制剂原发失败和既往暴露≥3种高级治疗与乌司奴单抗失败相关
核心结论
- 托法替布与乌司奴单抗在抗TNF治疗失败的溃疡性结肠炎患者中诱导和维持无激素缓解的疗效相似。
- 既往多种治疗失败(≥3种生物制剂)或任何生物制剂原发失败时,托法替布可能更受青睐。
研究设计与样本
- 多中心真实世界证据研究,连续纳入年龄≥18岁、既往暴露于抗TNF治疗、部分Mayo评分>2且开始托法替布或乌司奴单抗的溃疡性结肠炎患者。
- 托法替布组124例,乌司奴单抗组165例,所有比较均采用倾向性评分分析。
主要发现
- 任何生物制剂原发失败(OR 2.88,95%CI 1.20-6.98)和既往暴露≥3种高级治疗(OR 2.45,95%CI 1.03-5.82)与乌司奴单抗失败相关。
关键数值与推荐
- 第16周无激素症状缓解定义为部分Mayo评分≤2。
- 临床缓解按改良Mayo评分评估。
- 组织学与内镜改善为复合终点。
- 无激素缓解(CFREM)在第16周评估。
临床怎么用
- 抗TNF失败的UC患者可选择托法替布或乌司奴单抗,两者疗效总体相当。
- 对于既往暴露≥3种生物制剂或任何生物制剂原发失败的患者,可优先考虑托法替布。
局限性
- 真实世界研究设计可能存在未测量的混杂因素。
- 样本量有限,部分亚组分析置信区间较宽。
- 随访时间中位11.8个月,长期结局需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We compared the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-tumor necrosis factor (TNF) agent. METHODS: In this multicenter real-world evidence study, we consecutively included patients with UC ≥18 years old, previously exposed to anti-TNF therapy, with partial Mayo score >2 and, starting tofacitinib or ustekinumab. All the comparisons were performed using propensity score analyses. RESULTS: Overall, 124 and 165 patients were included in the tofacitinib and ustekinumab groups, respectively. Symptomatic remission, off corticosteroids (partial Mayo score ≤2) was achieved at week 16 in 37.8% and 35.8%, among the tofacitinib and ustekinumab groups, respectively (adjusted odds ratio [OR], 1.09; 95% confidence interval [CI], 0.60-2.00; P = .75), with higher tofacitinib effectiveness in patients with prior exposure to ≥3 biologics (46.7% vs 23.1%; adjusted OR, 2.92; 95% CI, 1.02-8.39; P = .047). Primary failure to any biologic (OR, 2.88; 95% CI, 1.20-6.98) and prior exposure to ≥3 advanced therapies (OR, 2.45; 95% CI, 1.03-5.82), but not disease severity, were associated with ustekinumab failure. We did not find any significant difference between tofacitinib and ustekinumab regarding clinical remission per modified Mayo score (17.0% vs 11.7%; adjusted OR, 1.55; 95% CI, 0.65-3.68; P = .32) and histological and endoscopic improvement (4.4% vs 7.8%; adjusted OR, 0.54; 95% CI, 0.16-1.86; P = .32). After a median follow-up of 11.8 months (interquartile range, 6.1-20.5 months), we did not observe any difference regarding the risk of UC relapse-related drug discontinuation (adjusted hazard ratio, 1.44; 95% CI, 0.94-2.21; P = .10), and the risk of secondary loss of response among patients achieving CFREM at week 16 (adjusted hazard ratio, 1.88; 95% CI, 0.57-6.19; P = .30). CONCLUSIONS: Tofacitinib and ustekinumab are similarly effective to induce and maintain corticosteroid-free remission after anti-TNF failure in UC. However, tofacitinib could be favored in case of multiple therapeutic failures (≥3 biologics) and primary failure to any biologic.
引用
- Buisson A, Serrero M, Altwegg R, et al. Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study. Clin Gastroenterol Hepatol. 2025. PMID: 40835043. doi:10.1016/j.cgh.2025.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。